UNSPSC 51292926: Opipramol dihydrochloride

This classification denotes an anxiolytic and antidepressant agent with the molecular formula C23H29N3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B49OBI656M, chemically known as 1-piperazineethanol, 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)-, dihydrochloride, but more generally known as opipramol dihydrochloride, which bears US NIH Compound Identifier 71587. European Medicines Agency schedules opipramol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09450MIG.

Most nations, for tariff purposes, schedule opipramol dihydrochloride under HS 29335995. SMILES: C1CCC2C(C1)C=CC3CCCCC3N2CCCN4CCN(CC4)CCO.CL.CL.

UNSPSC 51292926 Opipramol dihydrochloride is a Commodity code that nominally designates a specific antidepressant pharmaceutical product, but recent state and local solicitations tagged under this code show little relevant activity purchasing opipramol itself. Instead, the code has been applied to broader pharmaceutical and health-related procurement: naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The mismatch between the code's specific product name and the actual solicitations suggests either tagging inconsistency at the source or mission drift in how this code is being applied in practice. State and local purchasing offices, county health departments, and cooperative purchasing alliances (specifically Minnesota's MMCAP) are using this code, but the actual work spans emergency response supplies, pharmacy benefit programs, and multi-product pharmaceutical contracting rather than a single active pharmaceutical ingredient.

Recent activity includes Seminole County, Florida issuing an IFB (IFB60459723LAS, due July 26, 2026) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission posting an RFI (HHS0017013, closed April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities across Minnesota, Oregon, and other member jurisdictions through three authorized wholesalers. Geographic spread includes Florida, Texas, Minnesota, and Oregon, though the code shows limited recent activity overall relative to its nominal scope. Vendors pursuing work under this code should focus on broader pharmaceutical supply arrangements and cooperative purchasing agreements rather than opipramol as a standalone product line.